Evidence map›Paper›PMID 30782664›Full record

ArticlemBio2019

Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.

S F Bottom-Tanzer, K Rybkina, J N Bell, C A Alabi, C Mathieu, M Lu, S Biswas, M Vasquez, M Porotto, J A Melero and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Molecular Evolution of theMicroorganisms · 2025
    Article
  3. Article
  4. Article
  5. Antivirals targeting paramyxovirus membrane fusion.Current opinion in virology · 2021
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

S F Bottom-TanzerDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
K RybkinaDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
J N BellDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
C A AlabiRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
C MathieuDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
M LuDepartment of Microbiology, Biochemistry and Molecular Genetics, Rutgers Biomedical and Health Sciences, Public Health Research Institute, Newark, New Jersey, USA.
S BiswasDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
M VasquezCentro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
M PorottoDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA.
J A MeleroCentro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
V MásCentro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
A MosconaDepartment of Pediatrics, Columbia University Medical Center, New York, New York, USA am939@cumc.columbia.edu.
Columbia University Irving Medical Center · USCornell University · USCentre International de Recherche en Infectiologie · FRCentro de Investigación Biomédica en Red · ESCentro Nacional de Microbiologia · ESInstituto de Salud Carlos III · ESRutgers, The State University of New Jersey · US

Funding

Molecular basis for paramyxovirus entryR01AI031971 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 1998 to 2016
$6.6M
Engineering protease-resistant alpha-beta peptides for broad-spectrum antiviralsR01AI114736 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOSCONA, ANNE · 2015 to 2019
$3.7M
NIAID NIH HHS R01 AI031971NIAID NIH HHS R01 AI114736
6 · The paper itself

Abstract

Paramyxoviruses, specifically, the childhood pathogen human parainfluenza virus type 3, are internalized into host cells following fusion between the viral and target cell membranes. The receptor binding protein, hemagglutinin (HA)-neuraminidase (HN), and the fusion protein (F) facilitate viral fusion and entry into the cell through a coordinated process involving HN activation by receptor binding, which triggers conformational changes in the F protein to activate it to reach its fusion-competent state. Interfering with this process through premature activation of the F protein has been shown to be an effective antiviral strategy

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ViralAntiviral AgentsCell LineChlorocebus aethiopsHN ProteinHumansParainfluenza Virus 3, HumanProtein BindingProtein ConformationViral Fusion ProteinsViral Plaque AssayVirus InternalizationAntibodies, MonoclonalAntibodies, ViralAntiviral AgentsHN ProteinViral Fusion Proteinsantiviralconformational antibodyfusion activationparamyxovirusviral fusionviral glycoprotein antibody

Identifiers

PMID30782664
PMCPMC6381285
OpenAlexW2916045036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.